February 14, 2020
The Chase Group is proud to partner with Eli Lilly and support their commitment to developing innovative, breakthrough medicines that will make a meaningful difference for people with cancer and help them live longer healthier lives. With the recent acquisition of Loxo Oncology, Lilly has expanded the breadth of their oncology portfolio into precision medicine allowing them to target cancers that are caused by specific gene abnormalities. With the positive momentum of the new solid tumors and hematology programs, it is critical for Eli Lilly to add expertise to lead and manage the US and global medical affairs activities. To execute this key part of their oncology strategy, Eli Lilly has retained The Chase Group to identify and secure two Medical Affairs Leads to join this team to speed highly selective and innovative medicines to patients. For more information please contact moira@chasegroup.com
